Crocetin Attenuates Fibroblast-to-Myofibroblast Transition after Myocardial Infarction in Mice by Regulating Autophagy.

Abstract

PURPOSE: Myocardial infarction (MI) triggers pathological remodeling characterized by fibrosis and subsequent fibroblast-to-myofibroblast transition (FMT). Autophagy exerts a dual role in cardiac repair, balancing protective and detrimental effects. Crocetin, a carotenoid derived from saffron, exhibits anti-inflammatory and cardioprotective properties; however, its influence on autophagy-related FMT following MI remains unclear.This study aims to determine whether crocetin mitigates post-MI fibrosis and FMT by modulating autophagy in cardiac fibroblasts (CFs), while also evaluating its effects on cardiac function, infarct size, and autophagic flux. METHODS: In vivo: Mice subjected to MI were administered crocetin (25-100 mg/kg). Cardiac function was assessed via echocardiography, and fibrosis was evaluated through Masson's trichrome staining and immunofluorescence analysis for α-SMA/LC3. In vitro: Hypoxic CFs were treated with crocetin or the autophagy inhibitor 3-methyladenine (3-MA). The effects on autophagic flux (GFP-RFP-LC3), protein expression (Beclin-1, LC3-II/I, P62), and mitochondrial membrane potential (JC-1) were analyzed. RESULTS: Crocetin enhanced cardiac function, and reduced infarct size and fibrosis in a dose-dependent manner, while suppressing α-SMA expression. It promoted autophagic flux (as evidenced by increased LC3-II levels and autolysosome formation) and mitophagy (indicated by decreased mitochondrial membrane potential). Treatment with 3-MA negated the antifibrotic effects of crocetin. CONCLUSION: Crocetin attenuates post-MI pathological remodeling by enhancing autophagic flux to inhibit FMT, thereby identifying it as a promising candidate for antifibrotic therapy.